The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Can’t understand why NHS trial is for older people, surely if you want to test for early stage cancer you would target younger aga range.
Looks like it will be 2 years at least to gather any useful data, by that time Parsortix should be in daily use and approved.
Angle PLC Director/PDMR Shareholding
Source: UK Regulatory (RNS & others)
TIDMAGL
RNS Number : 5259J
Angle PLC
24 August 2021
For immediate release 24 August 2021
ANGLE plc
("ANGLE" or the "Company")
Director/PDMR Shareholding
Exercise of Options
and Total Voting Rights
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, announces that it has agreed to allot in total 500,000 new ordinary shares of 10 pence each in the capital of the Company ("Ordinary Shares"). This is following the exercise of share options by Ian Griffiths, Finance Director of the Company, at an exercise price of GBP0.2575 per Ordinary Share. The exercised share options pursuant to this transaction were due to expire in August 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.
Following the above transaction Mr. Griffiths' holdings in the Company will increase to 1,203,832 Ordinary Shares, representing approximately 0.5 per cent. of the Company's issued share capital. Mr Griffiths also holds share options over an additional 1,546,980 Ordinary Shares, and Long-Term Incentive Plan Options over up to a maximum of 3,600,000 additional Ordinary Shares, depending on performance conditions.
Application will be made to the London Stock Exchange for the 500,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 27 August 2021.
Following Admission, the total number of Ordinary Shares in issue will be 234,848,051 and the total number of voting rights will therefore be 234,848,051. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Contacts:
Angle PLC Study highlights superior performance of Parsortix
Angle PLC Contract secured for bespoke assay development
Brain cancer detection
770k already, 40 mins of trading !
Master stroke, overnight raise and no damage, dilution ok but worth it in the long run
Extract
Angle PLC ctDNA and CTCs have differences in EGFR mutations
Source: RNS Non-Regulatory
TIDMAGL
Angle PLC
18 June 2021
For immediate release 18 June 2021
ANGLE plc ("the Company")
DIFFERENCES FOUND IN EGFR MUTATIONS BETWEEN ctDNA AND CTCs IN MATCHED LIQUID BIOPSIES FROM NON-SMALL LUNG CANCER PATIENTS
Extract
Angle PLC Update on submission for FDA clearance
Source: RNS Non-Regulatory
TIDMAGL
Angle PLC
04 June 2021
For immediate release 4 June 2021
ANGLE plc ("the Company")
UPDATE ON SUBMISSION FOR FDA CLEARANCE OF THE PARSORTIX SYSTEM
Response to Additional Information Request made to FDA as planned
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, confirms that it has completed the work required to answer questions raised by FDA in its Additional Information Request and that a comprehensive response has been submitted to FDA as planned.
In line with industry best practice ANGLE does not intend to provide any further updates on communication with FDA regarding the submission whilst the regulatory process is as expected. ANGLE continues to anticipate a regulatory decision from FDA during H2 CY 2021*.
Extract from RNS
Angle PLC Potential to prevent breast cancer relapse
Source: UK Regulatory (RNS & others)
TIDMAGL
RNS Number : 2825A
Angle PLC
01 June 2021
For immediate release 1 June 2021
ANGLE plc ("the Company")
BREAKTHROUGH RESEARCH SUPPORTS POTENTIAL USE OF PARSORTIX IN PREVENTION OF RELAPSE OF BREAST CANCER PATIENTS IN REMISSION
Extract
Angle PLC Parsortix study uncovers targets in TNBC patients
Source: RNS Non-Regulatory
TIDMAGL
Angle PLC
11 May 2021
For immediate release 11 May 2021
ANGLE plc ("the Company")
NEW PARSORTIX STUDY UNCOVERS THERAPEUTIC TARGETS IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER
https://twitter.com/semicast_res/status/1388902207182065664?s=20